drugset / Trial / NCT06348134
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Non-randomizedCrossoverOpen-labelTreatment
Summary
Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2034-07-01
- Completion
- 2036-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Other |
| Subject | Pertuzumab | Monoclonal antibody | 600 mg | Subcutaneous |
| Subject | Trastuzumab emtansine | Other / unclassified | — | Intravenous |
| Background | Goserelin | Other / unclassified | 10.8 mg | Other |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Background | Tamoxifen | Small molecule | 20 mg | Oral |